Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769821 | 0.81 | KDM4E (0.50) | SMN1; SMN2KDM4EALDH1A1NPC1MEN1 | |
| SCHEMBL29488831 | 0.81 | ALDH1A1 (0.61) | SMN1; SMN2KDM4EALDH1A1GRM4NPC1 | |
| SCHEMBL568682 | 0.81 | ALDH1A1 (0.61) | SMN1; SMN2KDM4EALDH1A1GRM4NPC1 | |
| SCHEMBL20746280 | 0.80 | ALDH1A1 (0.54) | SMN1; SMN2KDM4EALDH1A1NPC1MEN1 | |
| SCHEMBL22026487 | 0.79 | KDM4E (0.63) | SMN1; SMN2KDM4EALDH1A1GRM4NPC1 | |
| SCHEMBL15494842 | 0.77 | ALDH1A1 (0.61) | SMN1; SMN2KDM4EALDH1A1GRM4NPC1 | |
| SCHEMBL30001187 | 0.77 | ALDH1A1 (0.61) | SMN1; SMN2KDM4EALDH1A1GRM4NPC1 | |
| SCHEMBL29735357 | 0.77 | ALDH1A1 (0.61) | SMN1; SMN2KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL106793 | 0.77 | ALDH1A1 (0.61) | SMN1; SMN2KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL3947482 | 0.77 | KDM4E (0.49) | SMN1; SMN2KDM4EALDH1A1GRM4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4347032-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117813302-A | Substituted tetrahydrofuran-2-carboxamides as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11918571-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2022256702-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022256702-A1 | SUBSTITUTED TETRAHYDROFURAN-2-CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115297861-A | Compound and use thereof | 福宏治疗公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220218681-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2022-07-14 | — | — | US | disclosed |
| US-11278535-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20200179358-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2020-06-11 | — | — | US | disclosed |
| WO-2019035951-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918571-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN2A | SMN1; SMN2 100/4885KDM4E 2508/4885ALDH1A1 1162/4885 |
| US-11278535-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN2A | SMN1; SMN2 100/4885KDM4E 2508/4885ALDH1A1 1162/4885 |
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | SMN1; SMN2 40/4885KDM4E 1848/4885ALDH1A1 2571/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | SMN1; SMN2 40/4885KDM4E 1848/4885ALDH1A1 2571/4885 |
| US-20200179358-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN2A | SMN1; SMN2 100/4885KDM4E 2508/4885ALDH1A1 1162/4885 |
| US-20220218681-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN2A | SMN1; SMN2 100/4885KDM4E 2508/4885ALDH1A1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.